TuanHoangVuMD

Neurology • Tampa, FL

Neuromuscular Medicine, Neurophysiology

Professor of Neurology, University S Fla College of Medicine

Join to view full profile

Dr. Vu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Vu's full profile

Already have an account?

Office
13220 USF Laurel Dr, Tampa, FL 33612
Tampa, FL 33612
Phone+1 813-974-9413

Fax+1 813-974-7138
Is this information wrong?

Education & Training

New York-Presbyterian HospitalPost-Doctoral Fellowship, Neuromuscular and Mitochondrial Disease Research, 1994 - 1996
New York Presbyterian Hospital (Columbia Campus)Fellowship, Neuromuscular Medicine (Neurology), 1993 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1990 - 1993
Penn State Milton S Hershey Medical CenterInternship, Internal Medicine, 1989 - 1990
Pennsylvania State University College of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2010 - 2026
PA State Medical License 1989 - 2010
NJ State Medical License 1994 - 2003
NY State Medical License 1992 - 2002
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine
American Board of Electrodiagnostic MedicineFellow

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Phase 3 Study of Dexpramipexole in ALS Start of enrollment: 2011 Mar 01
Completed
Phase 3
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis Start of enrollment: 2011 Jan 01
Completed
Not Applicable
Subcutaneous Immunoglobulin for CIDP Start of enrollment: 2014 Sep 01
Completed
Not Applicable
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Start of enrollment: 2017 May 15
Completed
Phase 2
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2017 Oct 11
Completed
Phase 2
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Start of enrollment: 2019 Jun 03
Completed
Phase 3
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Start of enrollment: 2021 Jun 28
Active, not recruiting
Phase 2
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) Start of enrollment: 2021 Dec 22
Active, not recruiting
Phase 2
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis Start of enrollment: 2021 Dec 14
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Vera Bril, James F Howard Jr, Chafic Karam, Jan L De Bleecker, Hiroyuki Murai, Kimiaki Utsugisawa, Peter Ulrichts, Edward Brauer, Sihui Zhao, Renato Mantegazza, Tuan Vu> ;European Journal of Neurology. 2024 Jan 1
15 citations
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-rand...
Volkan Granit, Michael Benatar, Metin Kurtoglu, Miloš D Miljković, Nizar Chahin, Gregory Sahagian, Marc H Feinberg, Adam Slansky, Tuan Vu, Christopher M Jewell, Michae...> ;The Lancet. Neurology. 2023 Jul 1
2 citations
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N Beasley, Nishi Rampal, James F Howard Jr> ;Neurology and Therapy. 2023 Oct 1
20 citations
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Liow, K. K., Howard, J., Bresch, S., Genge, A., Hewamadduma, C., Hinton, J., Hussain, Y., Juntas-Morales, R., Kaminski, H., Maniaol, A., Mantegazza, R., Masuda, M., Si...> ;The Lancet. Neurology. 2023 May 1
20 citations
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Ali Bozorg, ...> ;The Lancet. Neurology. 2023 May 1
12 citations
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMP...
Andreas Meisel, Djillali Annane, Tuan Vu, Renato Mantegazza, Masahisa Katsuno, Rasha Aguzzi, Glen Frick, Laura Gault, James F Howard Jr> ;Journal of Neurology. 2023 Aug 1
7 citations
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
Tuan Vu, Stephan Ortiz, Masahisa Katsuno, Djillali Annane, Renato Mantegazza, Kathleen N Beasley, Rasha Aguzzi, James F Howard Jr> ;Journal of Neurology. 2023 Jun 1
2 citations
Respiratory Strength Training in Amyotrophic Lateral Sclerosis: A Double-Blind, Randomized, Multicenter, Sham-Controlled Trial.
Emily K Plowman, Lauren T Gray, Jennifer Chapin, Amber Anderson, Terrie Vasilopoulos, Clifton Gooch, Tuan Vu, James P Wymer> ;Neurology. 2023 Apr 11
9 citations
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
Francesco Saccà, Carolina Barnett, Tuan Vu, Stojan Peric, Glenn A Phillips, Sihui Zhao, Cynthia Z Qi, Deborah Gelinas, Silvia Chiroli, Jan J G M Verschuuren> ;Journal of Neurology. 2023 Apr 1
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
Vu, T., Wiendl, H., Katsuno, M., Reddel, S., Howard, J.> ;Neuropsychiatric Disease and Treatment. 2023 Jan 1
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myast...
Howard, J., Bril, V., Vu, T., Karam, C., Peric, S., De Bleecker, J., Murai, H., Meisel, A., Beydoun, S., Pasnoor, M., Guglietta, A., Van Hoorick, B., Steeland, S., T'j...> ;Frontiers in Neurology. 2023 Jan 1
30 citations
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the...
Sabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, Newman Knowlton, James D Berry, Michael A Elliott, Samuel Maiser, Chafic Karam, James B Caress, Margaret Ayo Owegi...> ;Journal of Neurology, Neurosurgery, and Psychiatry. 2022 May 16
1 citations
Assessing gait, balance, and muscle strength among breast cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): study protocol for a randomized cont...
Patricia Teran-Wodzinski, Douglas Haladay, Tuan Vu, Ming Ji, Jillian Coury, Alana Adams, Lauren Schwab, Constance Visovsky> ;Trials. 2022 Apr 27
8 citations
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Merit Cudkowicz, Angela Genge, Nicholas J. Maragakis, Susanne Petri, Leonard H. van den Berg, Valtteri V Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al...> ;The Lancet. Neurology. 2021 Oct 1
122 citations
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Neurology. 2021 Jul 1
2 citations
Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunog...
Tuan Vu, Natalie Anthony, Raul Alsina, Brittany Harvey, Allison Schleutker, Jerrica R. Farias, Samuel Dang, Niraja Suresh, Clifton L. Gooch> ;Muscle & Nerve. 2021 Jun 2
87 citations
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis
Sabrina Paganoni, Suzanne Hendrix, Samuel P. Dickson, Newman Knowlton, Eric A. Macklin, James D. Berry, Michael A. Elliott, Samuel Maiser, Chafic Karam, James B. Cares...> ;Muscle & Nerve. 2021 Jan 1
17 citations
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized T...
Richard J. Barohn, Byron J. Gajewski, Mamatha Pasnoor, Alexandra R. Brown, Laura Herbelin, Kim S. Kimminau, Dinesh Pal Mudaranthakam, Omar Jawdat, Mazen M. Dimachkie, ...> ;JAMA Neurology. 2021 Jan 1
9 citations
Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
Tuan Vu, Brittany Harvey, Niraja Suresh, Jerrica R. Farias, Clifton L. Gooch> ;Case Reports in Neurology. 2021 Jan 1
204 citations
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Sabrina Paganoni, Eric A. Macklin, Suzanne Hendrix, James D. Berry, Michael A. Elliott, Samuel Maiser, Chafic Karam, James B. Caress, Margaret A. Owegi, Adam Quick, Ja...> ;The New England Journal of Medicine. 2020 Sep 2
37 citations
Clinical features of LRP4/agrin-antibody–positive myasthenia gravis: A multicenter study
Michael H. Rivner, Brandy Quarles, Jin-Xiu Pan, Zheng Yu, James F. Howard, Andrea M. Corse, Mazen M. Dimachkie, Carlayne E. Jackson, Tuan Vu, George A. Small, Robert P...> ;Muscle & Nerve. 2020 Sep 1
14 citations
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Renato Mantegazza, Fanny O'Brien, Marcus Yountz, James F. Howard, Claudio Mazia, Miguel Wilken, Fabio Barroso, Juliet Saba, Marcelo Rugiero, Mariela Bettini, Marcelo C...> ;Annals of Clinical and Translational Neurology. 2020 Aug 1
102 citations
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a ...
James F. Howard, Richard Nowak, Gil I. Wolfe, Miriam L. Freimer, Tuan Vu, John L. Hinton, Michael Benatar, Petra W. Duda, James E. MacDougall, Ramin Farzaneh-Far, Henr...> ;JAMA Neurology. 2020 May 1
4 citations
An Open-Label, Prospective Study Evaluating the Clinical and Immunological Effects of Higher Dose Granulocyte Colony-Stimulating Factor in ALS.
Kristyn Pocock, Niraja Suresh, Yazan Suradi, Samuel Dang, Brittany Harvey, Chuanhai Cao, Kyle Sutherland, Xiaoyang Lin, Tuan Vu, Clifton L. Gooch> ;Journal of Clinical Neuromuscular Disease. 2020 Mar 1
130 citations
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn, Isabel Illa, Saiju Jacob, John Vissing, Ted M. Burns, John T. Kissel, Richard...> ;Muscle & Nerve. 2019 Mar 8
Join now to see all

Journal Articles

Terminal Complement Inhibitory Ravulizumab in Generalized Myasthenia Gravis.
Tuan Vu, M.D.,1 Andreas Meisel, M.D.,2 Renato Mantegazza, M.D.,3 Djillali Annane, M.D.,4 Masahisa Katsuno, M.D.,5 Rasha Aguzzi, M.S.,6 Ahmed Enayetallah, M.D., Ph.D.,6..., NEJM Evidence 1 (5). April 2022., 4/2022

Press Mentions

Cartesian Therapeutics Expands Clinical Advisory Board with Five Internationally Recognized Experts in AutoimmunityMarch 28th, 2023

Grant Support

Mitochondrial DNA Depletion In Hepatoneural SyndromesNational Institute Of Neurological Disorders And Stroke2001
Mitochondrial DNA Depletion In Human DiseaseNational Institute Of Neurological Disorders And Stroke1996–2000